Issue Date: July 19, 2010
Service Firm Evotec Acquires DeveloGen
Evotec, a drug discovery and contract research firm, has agreed to acquire DeveloGen, a developer of small-molecule drugs based in Göttingen, Germany. Evotec will pay about $18 million and make future performance-related payments. Formed in 1997, DeveloGen has alliances with Boehringer Ingelheim on small-molecule diabetes treatments and with Andromeda Biotech on a synthetic peptide for diabetes. Evotec CEO Werner Lanthaler says the purchase adds to the firm’s list of high-value partnerships.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society